Hypoactive Sexual Desire Disorder: Advances in Diagnosis and Treatment
WebcastFaculty
OVERVIEW
Hypoactive Sexual Desire Disorder: Advances in Diagnosis and Treatment is organized by Omnia Education and will be held during May 18, 2017 - May 18, 2018.
The target audience for this medical event is Obstetricians/Gynecologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives. This CME Conference has been approved for a maximum of 0.25 AMA PRA Category 1 Credits.
Conference Objectives are :
After participating in this educational activity, participants should be better able to:
• Identify the symptoms of hypoactive sexual desire disorder.
• Cite barriers in their clinical practice that inhibit the appropriate diagnosis and management of HSDD.
• Identify the screening tools that allow for accurate diagnosis of HSDD.
• Identify the therapeutic modalities currently available, and in development, to manage HSDD including their benefits and potential side effects – also including the first agent approved for this indication (flibanserin).
• Identify the processes of the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) Program that will allow health care providers/pharmacies to prescribe/dispense flibanserin.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Obstetricians/Gynecologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives. This CME Conference has been approved for a maximum of 0.25 AMA PRA Category 1 Credits.
Conference Objectives are :
After participating in this educational activity, participants should be better able to:
• Identify the symptoms of hypoactive sexual desire disorder.
• Cite barriers in their clinical practice that inhibit the appropriate diagnosis and management of HSDD.
• Identify the screening tools that allow for accurate diagnosis of HSDD.
• Identify the therapeutic modalities currently available, and in development, to manage HSDD including their benefits and potential side effects – also including the first agent approved for this indication (flibanserin).
• Identify the processes of the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) Program that will allow health care providers/pharmacies to prescribe/dispense flibanserin.
Additional details will be posted as soon as they are available.
SPECIALITIES
PsychiatryRELATED ONLINE COURSES
By eMedEd, Inc.
Nov 28, 2024 - Nov 13, 2028 | Text-Based CME
State required course for Connecticut ...
3 Contact Hour
Quick Links